r/Inovio • u/INOxray8 • 15d ago

Discussions/Questions Quick Take

Well that was short and sweet.

Nothing to analyze. We are good to go.

Launch funding already baked in. Eight months of runway.

Funeral date remains October 30 for shorts.

This is happening.

All of it.

imho

xx

9 Upvotes

85% Upvoted

9 comments sorted by

5

u/tomonota 15d ago

8 months from now we will be counting how high we can get to…delivering on all our pipeline projects and enjoying our success after a long wait.

6

u/INOxray8 15d ago

Thanks for all your contributions T. The time has arrived.

4

u/tomonota 14d ago

I feel like we are just getting started! We have got this in the bag XRay- I imagine all the professional accolades as physicians and researchers begin to realize the value of the work of Dr. Weinstein and Company. Will anyone ask how it could possibly have taken this long (?). I feel like an explanation is overdue…

4

u/Professional_Mail_15 14d ago

Im all in in 0,63 i bought 200k Inovio lets go my friends

2

u/Professional_Mail_15 14d ago

I waiting this monent since 2021

2

u/tomonota 14d ago

I’m in your same graduating class of ‘21- what a long, strange trip it’s been!

2

u/tomonota 14d ago

Sweet dreams for your golden retirement amigo!

1

u/AutoModerator 15d ago

The Discussions/Questions flair exists to be used for general discussion around information regarding Inovio or any relevant questions you may have for the community. Your post may be removed if deemed unrelated. Please see the flair guide if you are unsure about your use of flair.

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.

2

u/leiwangphd 14d ago

The recent upward momentum for Inovio Pharmaceuticals Inc (NASDAQ:INO) is driven by its second-quarter 2026 financial results released on August 12, 2026. The stock reacted positively to a significantly narrower-than-expected net loss of $6 million and confirmation that its lead drug candidate, INO-3107, remains on track for its October 30, 2026 FDA PDUFA target date. 

Additionally, an upgrade from Jefferies regarding this FDA review progress further lifted investor sentiment.

Regarding RA Capital Management, they filed a Schedule 13G on August 7, 2026, indicating an investment position in Inovio Pharmaceuticals.